{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:19:18Z","timestamp":1787667558516,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multiple myeloma, a malignant plasma cell disorder, has undergone remarkable therapeutic advancement. The lenalidomide-bortezomib-dexamethasone (VRd) regimen has been firmly established as one of the standard induction therapies for newly diagnosed multiple myeloma (NDMM) patients, owing to its substantial clinical benefits. Despite its superiority in achieving good responses, VRd harbors intrinsic limitations in high relapse risk, and treatment-related toxicities. Dara (Daratumumab)-containing regimens are prioritized as frontline treatment options per international guidelines. While the quadruplet Dara-VRd combination further improves clinical efficacy, it carries notable safety and tolerability burdens and is suboptimal for vulnerable patient subgroups: it is poorly tolerated by elderly or frail individuals, requires complicated dose modifications for patients with renal impairment, and impairs hematopoietic stem cell mobilization in transplant-eligible candidates. The triplet daratumumab-bortezomib-dexamethasone (DVd) regimen has yielded encouraging anti-tumor activity in patients with relapsed\/refractory multiple myeloma (RRMM), which motivated us to explore its clinical performance in the frontline setting. The present study aimed to compare the efficacy and safety of frontline DVd versus VRd induction, to generate real-world clinical evidence guiding individualized treatment decision-making for NDMM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy, safety and real-world applicability of DVd versus VRd in NDMM patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter prospective study enrolled 206 NDMM patients (DVd:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200998; VRd:\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009108) from 12 Chinese centers (March 2023\u2013March 2025). Propensity score matching (PSM; covariates: age, serum creatinine, Durie-Salmon stage, ISS stage) generated a balanced cohort (70 patients\/group). Key endpoints: overall response rate (ORR), renal response rate (RRR), time to renal recovery (TTRR), progression-free survival (PFS), duration of response (DOR), and adverse events (AEs; NCI CTCAE v5.0).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Both groups had high completion rates after induction (95.9% [94\/98] vs. 94.4% [102\/108],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.623).\n                      <jats:bold>ORR<\/jats:bold>\n                      was comparable in the original cohort (DVd 97.9% vs. VRd 94.1%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.282), but DVd achieved faster response (median time to response: 1.85 vs. 2.27 months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), despite worse baseline characteristics. In the propensity score-matched cohort, the two groups also had similar ORR (DVd 97.1% vs. VRd 97.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20091.00) with comparable deep remission rates (MRD negativity: 4.3% vs. 7.3%; sCR\/CR: 30.4% vs. 32.3%).\n                      <jats:bold>Renal response:<\/jats:bold>\n                      Despite lower mean baseline eGFR in DVd group (23.7 vs. 32.7 mL\/min, p\u2009&lt;\u20090.001), magnitude of eGFR improvement was comparable (\u0394eGFR: 15.2 vs. 12.7 mL\/min, p\u2009=\u20090.48) in the original cohort. In the propensity score-matched cohort, 78.6% (22\/28) in DVd and 95.0% (19\/20) in VRd achieved response (renal-CR: 50.0% vs. 70.0%; renal-PR: 7.1% vs. 15.0%; renal-MR: 21.4% vs. 10.0%, p\u2009=\u20090.207).\n                      <jats:bold>PFS:<\/jats:bold>\n                      In the original cohort, the 12-month PFS rate was 92.8% in the DVd group and 79% in the VRd group. In the propensity score-matched cohort, the 12-month PFS rate in DVd and VRd group was 91.9% vs. 84%. Subgroup analyses confirmed PFS benefits in patients with high-risk genetics, ISS stage III, and transplant-eligible patients.\n                      <jats:bold>DOR:<\/jats:bold>\n                      In the original cohort, the 12-month DOR rate was 92.5% in the DVd group and 74.6% in the VRd group. In the propensity score-matched cohort cohort, the 12-month DOR rate in DVd and VRd group was 91.9% vs. 84%. Subgroup analyses confirmed DOR benefits in patients with high cytogenetic risk, ISS stage III, and transplant-eligible patients.\n                      <jats:bold>Safety:<\/jats:bold>\n                      Across both the original and PSM cohorts, the DVd regimen had relatively fewer severe adverse reactions than the VRd regimen with no statistical significance. After PSM, the patients in DVd group vs. VRd group: grade 3\u20134 neutropenia (5.71% vs. 10%, p\u2009=\u20090.346) and thrombocytopenia (10% vs. 14.29%, p\u2009=\u20090.438), grade 3\u20134 ALT elevation (7.14% vs. 10%, p\u2009=\u20090.546).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DVd demonstrates faster response, superior PFS and DOR, accompanying with relatively less toxicity in NDMM patients. These real-world data support DVd as a frontline option for NDMM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08637-6","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T03:44:31Z","timestamp":1786506271000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Superior 12-month progression-free survival with frontline DVd versus VRd in patients with newly diagnosed multiple myeloma: a multicenter propensity score-matched analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Huinan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"1","key":"8637_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s43556-024-00188-w","volume":"2024\u20137\u20134","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024;2024\u20137\u20134(1):25.","journal-title":"Mol Biomed"},{"issue":"9","key":"8637_CR2","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"2022\u20131\u20131","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. LANCET HAEMATOL. 2022;2022\u20131\u20131(9):e670\u20137.","journal-title":"LANCET HAEMATOL"},{"issue":"5","key":"8637_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/jnci\/djae321","volume":"2025\u20131\u20131","author":"A Mafra","year":"2025","unstructured":"Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, Mcshane C, Bray F, et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. JNCI: J Natl Cancer Inst. 2025;2025\u20131\u20131(5):907\u201314.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"8637_CR4","doi-asserted-by":"publisher","first-page":"217440","DOI":"10.1016\/j.canlet.2025.217440","volume":"2025\u20131\u20131","author":"X Dou","year":"2025","unstructured":"Dou X, Duan G, Zhong Y, Liu Y, Peng N, Wen L, et al. The burden of multiple myeloma in China: Trends from 1990 to 2021 and forecasts for 2050. CANCER LETT. 2025;2025\u20131\u20131:611: 217440.","journal-title":"CANCER LETT"},{"key":"8637_CR5","doi-asserted-by":"crossref","unstructured":"Wei JX, Shastri A, Sica RA, Mantzaris I, Kornblum N, Shah U, et al. Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis. Haematologica. 2024;109(5):1480-1486.","DOI":"10.3324\/haematol.2023.283304"},{"issue":"2","key":"8637_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/ejh.13349","volume":"2020\u20132\u20131","author":"K Okazuka","year":"2020","unstructured":"Okazuka K, Ishida T, Nashimoto J, Uto Y, Sato K, Miyazaki K, et al. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. EUR J HAEMATOL. 2020;2020\u20132\u20131(2):110\u20135.","journal-title":"EUR J HAEMATOL"},{"issue":"4","key":"8637_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"2024\u20131\u201325","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;2024\u20131\u201325(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"7","key":"8637_CR8","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41409-022-01697-4","volume":"2022\u20137\u20131","author":"MR Gaballa","year":"2022","unstructured":"Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, et al. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transpl. 2022;2022\u20137\u20131(7):1142\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"8637_CR9","doi-asserted-by":"crossref","unstructured":"Peipert JD, Zhao F, Lee J, Shen S, Ip E, O'Connell N, et al. Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma. JAMA Netw Open. 2024;7(3):e243854.","DOI":"10.1001\/jamanetworkopen.2024.3854"},{"key":"8637_CR10","doi-asserted-by":"crossref","unstructured":"Braga LP, de P\u00e1dua CAM, da Costa IHF, de Miranda Drummond PL, de Souza PHC, Fonseca LB, et al. Peripheral neuropathy associated with proteasome inhibitors and immunomodulatory drugs: a pharmacovigilance disproportionality analysis using VigiBase. Pharmacol Res Perspect. 2025;13(6):e70191.","DOI":"10.1002\/prp2.70191"},{"issue":"7","key":"8637_CR11","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/ajh.27314","volume":"2024\u20131\u20131","author":"BA Costa","year":"2024","unstructured":"Costa BA, Costa TA, Pak K, Patel A, Felix N, Mouhieddine TH, et al. Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta\u2010analysis. AM J HEMATOL. 2024;2024\u20131\u20131(7):1411\u20134.","journal-title":"AM J HEMATOL"},{"key":"8637_CR12","doi-asserted-by":"crossref","unstructured":"Laubach JP, Tai YT, Richardson PG, Anderson KC. Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014;23(4):445-452.","DOI":"10.1517\/13543784.2014.889681"},{"issue":"10","key":"8637_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.20.01849","volume":"2021\u20134\u20131","author":"KK Patel","year":"2021","unstructured":"Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. J CLIN ONCOL. 2021;2021\u20134\u20131(10):1119\u201328.","journal-title":"J CLIN ONCOL"},{"key":"8637_CR14","doi-asserted-by":"crossref","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):e825-e837.","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"8637_CR15","doi-asserted-by":"crossref","unstructured":"Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, et al. Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. Blood. 2022;140(6):594-607.","DOI":"10.1182\/blood.2021015220"},{"issue":"8","key":"8637_CR16","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1038\/bcj.2014.55","volume":"2014\u20138\u201315","author":"J Lu","year":"2014","unstructured":"Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. BLOOD CANCER J. 2014;2014\u20138\u201315(8):e239.","journal-title":"BLOOD CANCER J"},{"issue":"2","key":"8637_CR17","first-page":"130","volume":"2017\u20131\u201320","author":"Y Zhong","year":"2017","unstructured":"Zhong Y, Zhang Y, Liao A, Li S, Tian C, Lu J. Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China. Chin MED J-PEKING. 2017;2017\u20131\u201320(2):130\u20134.","journal-title":"Chin MED J-PEKING"},{"issue":"4","key":"8637_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/bjh.18703","volume":"2023\u20135\u20131","author":"A McMillan","year":"2023","unstructured":"McMillan A, Basu S, Karunanithi K, Parkins E, Lau E, Cook G, et al. Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis. Br J Haematol. 2023;2023\u20135\u20131(4):682\u20139.","journal-title":"Br J Haematol"},{"issue":"2","key":"8637_CR19","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/bjh.19936","volume":"2025\u20132\u20131","author":"I Vaxman","year":"2025","unstructured":"Vaxman I, Kumar S, Cohen I, Shimony S, Dispenzieri A, Buadi F, et al. Autologous stem cell transplantation for multiple myeloma patients whose myeloma-defining event was SLiM. Br J Haematol. 2025;2025\u20132\u20131(2):607\u201314.","journal-title":"Br J Haematol"},{"key":"8637_CR20","doi-asserted-by":"crossref","unstructured":"Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A. SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of \u2018biomarker-defined early multiple myeloma\u2019\u2014a systematic review with meta-analysis. EClinicalMedicine. 2023;58:101910.","DOI":"10.1016\/j.eclinm.2023.101910"},{"issue":"13","key":"8637_CR21","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","volume":"2016\u20131\u20131","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J CLIN ONCOL. 2016;2016\u20131\u20131(13):1544\u201357.","journal-title":"J CLIN ONCOL"},{"issue":"5","key":"8637_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.18568","volume":"2023\u20133\u20131","author":"T Etekal","year":"2023","unstructured":"Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, et al. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol. 2023;2023\u20133\u20131(5):587\u201394.","journal-title":"Br J Haematol"},{"issue":"10","key":"8637_CR23","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"2023\u20131\u20131","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. NAT MED. 2023;2023\u20131\u20131(10):2570\u20136.","journal-title":"NAT MED"},{"key":"8637_CR24","doi-asserted-by":"crossref","unstructured":"Tan C, Nemirovsky D, Derkach A, Hultcrantz M, Hassoun H, Mailankody S, et al. Carfilzomib, lenalidomide and dexamethasone (KRd) vs bortezomib, lenalidomide, and dexamethasone (VRd) as induction therapy in newly diagnosed high-risk multiple myeloma. Blood. 2022;140(Suppl 1):1817-1819.","DOI":"10.1182\/blood-2022-169161"},{"issue":"11","key":"8637_CR25","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"2023\u201311\u20131","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. LANCET HAEMATOL. 2023;2023\u201311\u20131(11):e890\u2013901.","journal-title":"LANCET HAEMATOL"},{"issue":"25","key":"8637_CR26","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"2022\u20139\u20131","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J CLIN ONCOL. 2022;2022\u20139\u20131(25):2901\u201312.","journal-title":"J CLIN ONCOL"},{"issue":"1","key":"8637_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-024-01096-6","volume":"2024\u20137\u201319","author":"B Ziccheddu","year":"2024","unstructured":"Ziccheddu B, Giannotta C, D\u2019Agostino M, Bertuglia G, Saraci E, Oliva S, et al. Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma. BLOOD CANCER J. 2024;2024\u20137\u201319(1):117.","journal-title":"BLOOD CANCER J"},{"issue":"3","key":"8637_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-022-00645-1","volume":"2022\u20133\u201328","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi AH, Al HR, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. BLOOD CANCER J. 2022;2022\u20133\u201328(3):47.","journal-title":"BLOOD CANCER J"},{"issue":"32","key":"8637_CR29","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.21.01045","volume":"2021\u201311\u201310","author":"P Sonneveld","year":"2021","unstructured":"Sonneveld P, Dimopoulos MA, Beksac M, van der Holt B, Aquino S, Ludwig H, et al. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. J CLIN ONCOL. 2021;2021\u201311\u201310(32):3613\u201322.","journal-title":"J CLIN ONCOL"},{"key":"8637_CR30","doi-asserted-by":"crossref","unstructured":"Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, et al. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: findings from the MASTER and GRIFFIN trials. Transplant Cell Ther. 2023;29(3):171-174.","DOI":"10.1016\/j.jtct.2022.11.029"},{"key":"8637_CR31","doi-asserted-by":"crossref","unstructured":"Offidani M, Corvatta L, Mor\u00e8 S, Nappi D, Martinelli G, Olivieri A, et al. Daratumumab for the management of newly diagnosed and relapsed\/refractory multiple myeloma: current and emerging treatments. Front Oncol. 2021;10:624661.","DOI":"10.3389\/fonc.2020.624661"},{"key":"8637_CR32","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Calle V, Rodr\u00edguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, et al. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study. Haematologica. 2024;109(7):2219.","DOI":"10.3324\/haematol.2023.284089"},{"key":"8637_CR33","doi-asserted-by":"crossref","unstructured":"Naicker SD, Feerick CL, Lynch K, Swan D, McEllistrim C, Henderson R, et al. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody-dependent cellular phagocytosis. Oncoimmunology. 2021;10(1):1859263.","DOI":"10.1080\/2162402X.2020.1859263"},{"issue":"7","key":"8637_CR34","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","volume":"2021\u20137\u20131","author":"JL Thangaraj","year":"2021","unstructured":"Thangaraj JL, Ahn SY, Jung SH, Vo MC, Chu TH, Thi PM, et al. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. CELL MOL IMMUNOL. 2021;2021\u20137\u20131(7):1652\u201361.","journal-title":"CELL MOL IMMUNOL"},{"issue":"4","key":"8637_CR35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/bjh.18703","volume":"2023\u20131\u20131","author":"A McMillan","year":"2023","unstructured":"McMillan A, Basu S, Karunanithi K, Parkins E, Lau EYM, Cook G, et al. Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysis. BRIT J HAEMATOL. 2023;2023\u20131\u20131(4):682\u20139.","journal-title":"BRIT J HAEMATOL"},{"key":"8637_CR36","doi-asserted-by":"crossref","unstructured":"Zhou X, Hofmann A, Engel B, Vogt C, Nerreter S, Tamamushi Y, et al. Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk multiple myeloma. Hemasphere. 2025;9(1):e70078.","DOI":"10.1002\/hem3.70078"},{"key":"8637_CR37","doi-asserted-by":"crossref","unstructured":"Gooding S, Ansari-Pour N, Towfic F, Ortiz Est\u00e9vez M, Chamberlain PP, Tsai K, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137(2):232-237.","DOI":"10.1182\/blood.2020007081"},{"key":"8637_CR38","doi-asserted-by":"crossref","unstructured":"Teoh PJ, Koh MY, Mitsiades C, Gooding S, Chng WJ. Resistance to immunomodulatory drugs in multiple myeloma: the cereblon pathway and beyond. Haematologica. 2025;110(5):1074-1091.","DOI":"10.3324\/haematol.2024.285636"},{"issue":"3","key":"8637_CR39","first-page":"421","volume":"2024\u20132\u20131","author":"W Yan","year":"2024","unstructured":"Yan W, Xu J, Fan H, Li L, Cui J, Du C, et al. Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma. CANCER-AM CANCER SOC. 2024;2024\u20132\u20131(3):421\u201332.","journal-title":"CANCER-AM CANCER SOC"},{"key":"8637_CR40","doi-asserted-by":"crossref","unstructured":"Forde K, Cocks K, Wells JR, McMillan I, Kyriakou C, EORTC QOLG. Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development. Blood Cancer J. 2023;13(1):79.","DOI":"10.1038\/s41408-023-00815-9"},{"issue":"1","key":"8637_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41408-024-01177-6","volume":"2024\u201311\u201311","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Lee HC, Omel J, Toomey K, Hardin JW, Gasparetto CJ, et al. Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect(R) MM Registry. BLOOD CANCER J. 2024;2024\u201311\u201311(1):198.","journal-title":"BLOOD CANCER J"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08637-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08637-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08637-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:26:23Z","timestamp":1787664383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08637-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8637"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08637-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"24 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1091"}}